Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-Verify Now Trial).

Suh JW, Kim CH, Oh IY, Yoon CH, Kim KI, Cho YS, Youn TJ, Chae IH, Choi DJ.

Am J Cardiol. 2012 Dec 15;110(12):1749-55. doi: 10.1016/j.amjcard.2012.08.009. Epub 2012 Sep 19.

PMID:
22999073
2.

Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.

Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G.

JACC Cardiovasc Interv. 2010 Mar;3(3):318-23. doi: 10.1016/j.jcin.2009.12.012.

3.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

4.

Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.

Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciascio G.

Am J Cardiol. 2010 Sep 1;106(5):619-23. doi: 10.1016/j.amjcard.2010.04.015.

PMID:
20723634
5.

Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.

Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E.

J Am Coll Cardiol. 2013 Jan 8;61(1):23-34. doi: 10.1016/j.jacc.2012.09.037.

7.

Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).

Patti G, Mangiacapra F, Ricottini E, Cannatà A, Cavallari I, Vizzi V, D'Ambrosio A, Dicuonzo G, Di Sciascio G.

Am J Cardiol. 2013 Jun 15;111(12):1739-44. doi: 10.1016/j.amjcard.2013.02.028. Epub 2013 Mar 26.

PMID:
23538022
8.
9.

Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization.

Verdoia M, Barbieri L, Schaffer A, Cassetti E, Marino P, Bellomo G, Sinigaglia F, De Luca G; Novara Atherosclerosis Study Group (NAS)..

Heart Vessels. 2015 Jan;30(1):20-7. doi: 10.1007/s00380-013-0449-4. Epub 2013 Dec 3.

PMID:
24297745
10.

Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.

Bertrand OF, Rodés-Cabau J, Rinfret S, Larose E, Bagur R, Proulx G, Gleeton O, Costerousse O, De Larochellière R, Roy L.

Am J Cardiol. 2009 Nov 1;104(9):1235-40. doi: 10.1016/j.amjcard.2009.06.036.

PMID:
19840568
11.

Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.

Leonardi S, Thomas L, Neely ML, Tricoci P, Lopes RD, White HD, Armstrong PW, Giugliano RP, Antman EM, Califf RM, Newby LK, Mahaffey KW.

J Am Coll Cardiol. 2012 Dec 4;60(22):2296-304. doi: 10.1016/j.jacc.2012.09.005. Epub 2012 Nov 1.

12.

Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.

Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.

Am J Cardiol. 2007 Jun 1;99(11):1518-22. Epub 2007 Apr 13.

PMID:
17531573
13.

Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.

Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW; On-TIME 2 Trial Investigators..

J Invasive Cardiol. 2012 Mar;24(3):84-9.

14.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators..

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

15.

Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.

Gulmez O, Yildirir A, Kaynar G, Konas D, Aydinalp A, Ertan C, Ozin B, Muderrisoglu H.

J Thromb Thrombolysis. 2008 Jun;25(3):239-46. Epub 2007 Jun 16.

PMID:
17574519
16.
17.

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up..

N Engl J Med. 2001 Jun 21;344(25):1895-903.

19.

Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.

Karha J, Gurm HS, Rajagopal V, Fathi R, Bavry AA, Brener SJ, Lincoff AM, Ellis SG, Bhatt DL.

Am J Cardiol. 2006 Oct 1;98(7):906-10. Epub 2006 Aug 17.

PMID:
16996871
20.

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.

Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators..

Eur Heart J. 2000 Dec;21(24):2042-55.

PMID:
11102255

Supplemental Content

Support Center